Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort

Lung, Respiratory and Thoracic Cancer

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective

Lung Cancer

Grit GF, van Geffen E, Malmberg R, van Leeuwen R, Böhringer S, Jm Smit H, Brocken P, Fh Eijsink J, Dronkers E, Gal P, Jaarsma E, Jhm van Drie-Pierik R, Mp Eldering-Heldens A, Machteld Wymenga AN, Gm Mol P, Zwaveling J, Hilarius D

doi: 10.1016/j.lungcan.2024.107950

Lung, Respiratory and Thoracic Cancer

The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study

Lung Cancer

de Ruiter JC, van der Noort V, van Diessen JNA, Smit EF, Damhuis RAM, Hartemink KJ, ESLUNG group

doi: 10.1016/j.lungcan.2024.107792

Lung, Respiratory and Thoracic Cancer

Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition

Lung Cancer

Saal J, Bald T, Eckstein M, Ralser DJ, Brossart P, Ellinger J, Hölzel M, Klümper N

doi: 10.1016/j.lungcan.2024.107505

Lung, Respiratory and Thoracic Cancer

Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study

Lung Cancer

Pons-Tostivint E, Ezzedine R, Goronflot T, Crequit P, Chatellier T, Raimbourg J, Bennouna J, Giroux Leprieur E, Porte M

doi: 10.1016/j.lungcan.2024.107887

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Long term outcomes after lobar versus sublobar resection for patients with Non-Small cell lung Cancer: Systematic review and individual patient data Meta-Analysis

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Tasoudis P, Loufopoulos G, Manaki V, Doerr M, Agala CB, Long JM, Haithcock BE

doi: 10.1016/j.lungcan.2024.107929

Lung, Respiratory and Thoracic Cancer

Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort

Lung Cancer

Swalduz A, Beau-Faller M, Planchard D, Mazieres J, Bayle-Bleuez S, Debieuvre D, Fallet V, Geier M, Cortot A, Couraud S, Daniel C, Domblides C, Pichon E, Fabre E, Larivé S, Lerolle U, Tomasini P, Wislez M, Missy P, Morin F, Westeel V, Auliac JB

doi: 10.1016/j.lungcan.2024.108038

Genitourinary Cancer

Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database

Prostate Cancer Prostatic Dis

Eule CJ, Warren A, Molina Kuna E, Robin TP, Gershman B, Kim SP, Flaig TW

doi: 10.1038/s41391-024-00914-z

Lung, Respiratory and Thoracic Cancer

Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up

J Thorac Oncol

Gadgeel SM, Rodríguez-Abreu D, Halmos B, Garassino MC, Kurata T, Cheng Y, Jensen E, Shamoun M, Rajagopalan K, Paz-Ares L

doi: 10.1016/j.jtho.2024.04.011

Lung, Respiratory and Thoracic Cancer

Optimizing Treatment Strategies for Egfr-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and Insights

Cancers (Basel)

Thomas QD, Girard N, Bosquet L, Cavaillon S, Filleron T, Eltaief S, Chouaid C, Lena H, Debieuvre D, Perol M, Quantin X

doi: 10.3390/cancers16213563

Related content

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective

The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study

Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition

Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study

Long term outcomes after lobar versus sublobar resection for patients with Non-Small cell lung Cancer: Systematic review and individual patient data Meta-Analysis

Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort

Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database

Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up

Optimizing Treatment Strategies for Egfr-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and Insights